Spots Global Cancer Trial Database for azd2281
Every month we try and update this database with for azd2281 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Assessment of Efficacy of AZD2281 in Platinum Sensitive Relapsed Serous Ovarian Cancer | NCT00753545 | Ovarian Cancer | AZD2281 matching placeb... | 18 Years - 130 Years | AstraZeneca | |
| Study to Assess Safety & Tolerability of AZD2281 in Combination With Bevacizumab in Patients With Advanced Solid Tumours | NCT00710268 | Neoplasm Metast... | AZD2281 Bevacizumab | 18 Years - | AstraZeneca | |
| Study Assessing Metabolism, Excretion and Pharmacokinetics of a Poly (ADP-Ribose) Polymerase (PARP) Inhibitor in Patients With Solid Metastatic Tumours | NCT00633269 | Neoplasm Metast... | AZD2281 | 18 Years - | AstraZeneca | |
| Phase Ib Study of Olaparib Plus Weekly Carboplatin and Paclitaxel in Relapsed Ovarian Cancer | NCT01650376 | Stage III Ovari... Stage IV Ovaria... Uterine Cancer | Olaparib Carboplatin Paclitaxel | 18 Years - | Swedish Medical Center | |
| OLAParib COmbinations | NCT02576444 | Cancer | AZD2281 AZD5363 AZD1775 AZD6738 | 18 Years - | Yale University | |
| AZD2281 in Combination With Liposomal Doxorubicin in Advanced Solid Tumours | NCT00819221 | Solid Tumors | AZD2281 liposomal doxor... | 18 Years - 130 Years | AstraZeneca | |
| Phase I Comparative Bioavailability Study | NCT00777582 | Solid Tumors | AZD2281 | 18 Years - 130 Years | AstraZeneca | |
| OLAParib COmbinations | NCT02576444 | Cancer | AZD2281 AZD5363 AZD1775 AZD6738 | 18 Years - | Yale University | |
| Phase I/II Study of AZD2281 Given in Combination With Paclitaxel in Metastatic Triple Negative Breast Cancer | NCT00707707 | Breast Cancer Triple Negative... Metastatic Brea... | AZD2281 Paclitaxel | 18 Years - 130 Years | AstraZeneca | |
| Study to Assess the Efficacy and Safety of a PARP Inhibitor for the Treatment of BRCA-positive Advanced Ovarian Cancer | NCT00494442 | Ovarian Neoplas... | KU-0059436 (AZD... KU-0059436 (AZD... | 18 Years - 130 Years | AstraZeneca | |
| Dose-finding Study Comparing Efficacy and Safety of a PARP Inhibitor Against Doxil in BRCA+ve Advanced Ovarian Cancer | NCT00628251 | Ovarian Neoplas... | AZD2281 Liposomal Doxor... AZD2281 | 18 Years - 130 Years | AstraZeneca | |
| Dose-finding Study Comparing Efficacy and Safety of a PARP Inhibitor Against Doxil in BRCA+ve Advanced Ovarian Cancer | NCT00628251 | Ovarian Neoplas... | AZD2281 Liposomal Doxor... AZD2281 | 18 Years - 130 Years | AstraZeneca | |
| Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer | NCT02546661 | Muscle Invasive... | AZD4547 MEDI4736 Olaparib AZD1775 Vistusertib AZD9150 Selumetinib | 18 Years - 130 Years | AstraZeneca | |
| Study to Assess Safety & Tolerability of AZD2281 in Combination With Bevacizumab in Patients With Advanced Solid Tumours | NCT00710268 | Neoplasm Metast... | AZD2281 Bevacizumab | 18 Years - | AstraZeneca | |
| Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer | NCT02546661 | Muscle Invasive... | AZD4547 MEDI4736 Olaparib AZD1775 Vistusertib AZD9150 Selumetinib | 18 Years - 130 Years | AstraZeneca | |
| Study to Assess the Efficacy and Safety of a PARP Inhibitor for the Treatment of BRCA-positive Advanced Ovarian Cancer | NCT00494442 | Ovarian Neoplas... | KU-0059436 (AZD... KU-0059436 (AZD... | 18 Years - 130 Years | AstraZeneca |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
